DRD5 and inflammatory bowel disease: In this study, we found that the administration of D1-like agonist (prefer to target DRD5) attenuates the colitogenic phenotype of mice, suggesting targeting of DRD5 signaling could be a potential therapeutic manipulation to treat IBD.